REVELATION BIOSCIENCES, INC.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Research and development | $4.1M | $3.5M | $4.1M | $5.4M | $6.9M |
| Operating expenses | $9.1M | $8.0M | $8.7M | $10.9M | $12.0M |
| Operating income | -$9.1M | -$8.0M | -$8.7M | -$10.9M | -$12.0M |
| Interest expense | — | — | — | — | $41,759 |
| Income tax expense | $0 | $0 | $0 | $0 | $0 |
| Net income | -$8.9M | -$15.0M | -$120,254 | -$10.8M | -$12.0M |
| Balance Sheet | |||||
| Cash and equivalents | $10.7M | $6.5M | $12.0M | $5.3M | $1.3M |
| Current assets | $10.8M | $6.6M | $12.1M | $5.4M | $1.9M |
| Total assets | $11.6M | $6.6M | $12.2M | $5.5M | $2.0M |
| Current liabilities | $2.0M | $1.9M | $5.6M | $4.5M | $2.1M |
| Total liabilities | $2.7M | $1.9M | $5.6M | $4.5M | $2.1M |
| Stockholders' equity | $8.9M | $4.7M | $6.6M | $1.1M | -$99,470 |
| Cash Flow Statement | |||||
| Cash from operations | -$8.3M | -$18.3M | -$7.3M | -$11.2M | -$11.1M |
| Depreciation and amortization | $27,058 | $27,923 | $25,049 | $25,048 | $16,782 |
| Stock-based compensation | $595,368 | $168,850 | $155,721 | $301,116 | $470,878 |
| Capital expenditure | — | $19,171 | — | — | $131,963 |
| Free cash flow | — | -$18.3M | — | — | -$11.2M |
| Share repurchases | — | — | — | — | $35.5M |
Shares outstanding 3.9M · Free float 35.3%
Annual filing data through FY ended December 31, 2025; float as of July 15, 2026.